ATIVAN Drug Patent Profile

Which patents cover Ativan, and what generic alternatives are available?

Ativan is a drug marketed by Hikma and Bausch and is included in two NDAs.

The generic ingredient in ATIVAN is lorazepam. There are eleven drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lorazepam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ativan

A generic version of ATIVAN was approved as lorazepam by SANDOZ on April 21^st, 1987.

Summary for ATIVAN

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	50
Clinical Trials:	44
Patent Applications:	4,361
Drug Prices:	Drug price information for ATIVAN
What excipients (inactive ingredients) are in ATIVAN?	ATIVAN excipients list
DailyMed Link:	ATIVAN at DailyMed

See drug prices for ATIVAN

See drug sales revenues for ATIVAN

Recent Clinical Trials for ATIVAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
California Institute of Technology	Phase 4
Laureate Institute for Brain Research, Inc.	Phase 4
Temple University	Phase 4

See all ATIVAN clinical trials

Pharmacology for ATIVAN

Drug Class

Benzodiazepine

US Patents and Regulatory Information for ATIVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	ATIVAN	lorazepam	INJECTABLE;INJECTION	018140-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Bausch	ATIVAN	lorazepam	TABLET;ORAL	017794-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Hikma	ATIVAN	lorazepam	INJECTABLE;INJECTION	018140-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Bausch	ATIVAN	lorazepam	TABLET;ORAL	017794-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Expired US Patents for ATIVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hikma	ATIVAN	lorazepam	INJECTABLE;INJECTION	018140-001	Approved Prior to Jan 1, 1982	4,017,616
Hikma	ATIVAN	lorazepam	INJECTABLE;INJECTION	018140-002	Approved Prior to Jan 1, 1982	4,017,616

International Patents for ATIVAN

See the table below for patents covering ATIVAN around the world.

Country	Patent Number	Title	Estimated Expiration
France	2181679
United Kingdom	1345510
Belgium	794224
Australia	5024072

Benzodiazepine Drugs Market Dynamics and Financial Trajectory: Focus on Ativan (Lorazepam)

Market Overview

The global benzodiazepine drugs market, which includes medications like Ativan (Lorazepam), is poised for steady growth driven by several key factors.

Rising Incidence of Anxiety and Stress Disorders

The increasing prevalence of anxiety and stress-related disorders, exacerbated by fast-paced lifestyles, economic pressures, and the aftermath of events like the COVID-19 pandemic, has significantly boosted the demand for benzodiazepine medications. This trend is expected to continue, driving market growth[3][4].

Market Size and Growth Projections

Global Market Value

The global benzodiazepine drugs market is projected to reach approximately US$ 3.1 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 2.8% from 2022 to 2032. This growth is largely attributed to the rising use of benzodiazepines for mental health disorders and the development of new medications with minimal side effects[1][4].

Segment Growth: Lorazepam (Ativan)

Lorazepam, marketed under the brand name Ativan, is a significant segment within the benzodiazepine market. The Lorazepam market is expected to grow sustainably, driven by its applications in treating anxiety disorders, insomnia, seizure management, and pre-procedural sedation. The market for Lorazepam is anticipated to expand due to increasing prescription rates, particularly among older adults who are at a higher risk of these conditions[3].

Distribution Channels

Retail Pharmacies, Hospitals, and Online Pharmacies

The distribution of benzodiazepine drugs, including Lorazepam, is segmented into retail pharmacies, hospitals, and online pharmacies. Hospitals are a preferred distribution channel due to their accessibility and treatment convenience. Retail pharmacies and online pharmacies also play crucial roles, offering convenience and accessibility to a broader patient base[4].

Regional Market Dynamics

North America and APAC

North America currently holds the largest market share in the benzodiazepine drugs market, driven by substantial research investments and the presence of significant pharmaceutical corporations. However, the Asia-Pacific (APAC) region is expected to grow at the fastest rate over the forecast period, driven by increasing awareness of mental health issues and growing healthcare infrastructure[4].

Key Drivers

Increasing Urbanization and Work Pressure

Urbanization and the associated work pressure have significantly increased mental health problems, creating a huge growth opportunity for benzodiazepine drug manufacturers. The fast-paced lifestyle and financial pressures contribute to the rising demand for these medications[1][3].

Growing Awareness and Reduced Stigma

Growing awareness of mental health concerns and a reduction in the stigma attached to anxiety disorders have promoted the behavior of seeking treatment. This shift has led to more patients potentially benefiting from benzodiazepines like Lorazepam[3][4].

Aging Population

The growing older population is another key driver, as older adults are at a higher risk of anxiety disorders and insomnia, leading to increased prescription rates for Lorazepam[3].

Challenges

Potential for Abuse and Dependence

One of the significant challenges facing the Lorazepam market is the potential for abuse and dependence. Strict laws and educational initiatives are essential to mitigate these risks. Additionally, competition from alternative anxiety therapies, such as mindfulness exercises and cognitive behavioral therapy (CBT), poses a challenge to the market[3].

Adverse Effects

The possibility of adverse effects, such as sleepiness and cognitive impairment, particularly in older persons or those who need to be awake throughout the day, is another challenge. Developing safer and more targeted medications remains a critical area of focus[3].

Opportunities

Advancements in Drug Delivery Systems

Advancements in drug delivery systems, such as new formulations with higher absorption rates or fewer adverse effects, present significant opportunities for the Lorazepam market. Personalized medicine and the increasing emphasis on genetic variables in drug efficacy also offer avenues for individualized treatment regimens[3].

Telemedicine

The growing use of telemedicine provides better access to medicines, especially for patients in remote areas or with limited mobility. This trend is expected to enhance the market for Lorazepam by facilitating online consultations and prescriptions[3].

Key Players

Major players in the benzodiazepine drugs market, including those manufacturing Lorazepam, are actively involved in new product development, mergers and acquisitions, and strategic alliances. Companies such as Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals PLC are prominent in this space[3][4].

Recent Developments

In May 2023, Hikma Pharmaceuticals PLC launched Diazepam Injection, USP, which is used to treat anxiety-related disorders and provide short-term relief. Such product launches and innovations are expected to drive market growth[4].

Financial Trajectory

Short Term (2022 to 2025)

The short-term growth of the benzodiazepine drugs market, including Lorazepam, will be favorably affected by the rising use of these medications for mental health disorders. This period will see increased demand due to the ongoing need for effective treatments for anxiety and stress-related conditions[1].

Medium Term (2025 to 2028)

During the medium term, product development with minimal side effects will lead to huge acceptance of benzodiazepine drugs. This period will witness significant investments in research and development aimed at improving the safety and efficacy of these medications[1].

Long Term (2028 to 2032)

In the long term, rising urbanization and extraordinary work pressure will continue to drive market growth. The aging population and increasing awareness of mental health issues will also contribute to the sustained growth of the benzodiazepine market, including the segment for Lorazepam[1].

Key Takeaways

• The global benzodiazepine drugs market, including Lorazepam, is expected to grow at a CAGR of 2.8% to reach US$ 3.1 billion by 2032.
• Rising incidence of anxiety and stress disorders, growing awareness, and reduced stigma are key drivers.
• The aging population and urbanization are significant factors contributing to market growth.
• Challenges include potential for abuse and dependence, adverse effects, and competition from alternative therapies.
• Advancements in drug delivery systems, personalized medicine, and telemedicine offer opportunities for growth.

FAQs

What is the projected market size for benzodiazepine drugs by 2032?

The global benzodiazepine drugs market is projected to reach approximately US$ 3.1 billion by 2032.

What are the primary drivers of the Lorazepam market?

The primary drivers include the rising incidence of anxiety and stress disorders, growing awareness and reduced stigma, and the increasing older population.

What are the main challenges facing the Lorazepam market?

The main challenges include the potential for abuse and dependence, adverse effects, and competition from alternative anxiety therapies.

How is the distribution of benzodiazepine drugs segmented?

The distribution is segmented into retail pharmacies, hospitals, and online pharmacies.

What role does telemedicine play in the Lorazepam market?

Telemedicine provides better access to medicines, especially for patients in remote areas or with limited mobility, facilitating online consultations and prescriptions.

Which regions are expected to drive the growth of the benzodiazepine market?

North America currently holds the largest market share, but the APAC region is expected to grow at the fastest rate over the forecast period.

Sources

1. Fact.MR: Benzodiazepine Drugs Market Size, Share & Growth Trajectory 2032
2. MDPI: Benzodiazepine Trajectories and Injurious Fall Risk among US Medicare Beneficiaries
3. HTF Market Intelligence: Lorazepam Market - Global Trend and Growth Outlook to 2030
4. Grand View Research: Benzodiazepine Drugs Market Size And Share Report, 2030